Most pre-IPO content is written for buyers. But there's a large group with a more pressing problem: people who already own private company stock and have no idea how to turn it into money.
If you're an employee sitting on vested shares, a former employee who exercised options on the way out, or an early investor whose position has appreciated for years on paper, you know the frustration. The valuation headlines say your stake is worth a fortune. Your bank account disagrees. And the IPO keeps getting pushed — Databricks moved its long-expected listing toward 2027, with CEO Ali Ghodsi saying plainly, "We will be a public company. I just think this is a terrible year to go public."
This guide covers your actual options for selling pre-IPO shares in 2026, the approval process nobody warns you about, and how to think about timing.
Your Four Paths to Liquidity
Path | Who controls timing | Best for |
|---|---|---|
Company-sponsored tender offer | The company | Clean execution, but only when a window opens |
Secondary market sale | You | Liquidity on your own timeline |
Wait for IPO or acquisition | Nobody, really | Maximum upside, unbounded timeline |
Share-backed financing | Lender terms | Cash without selling — but adds real risk |
1. Company-sponsored tender offers
A tender offer is a structured liquidity event the company runs itself: it sets a price, opens a window (typically two to four weeks), and lets eligible shareholders sell a defined portion of their holdings.
This is usually the cleanest path when available — approval is built in, pricing is set, and the process is administered for you. The catch is that you don't control when it happens.
The good news is that tenders have become far more common. Roughly 1,400 active private-market issuers were tracked as of mid-2026, and about 110 ran a board-sponsored tender in the prior 12 months — roughly triple the 2021 level. Nasdaq Private Market alone executed about $15 billion in tender volume in 2025, up from roughly $3 billion in 2023.
Liquidity is also arriving earlier in a company's life: about 50% of Nasdaq Private Market tender programs in 2025 involved Series A–C companies, up from around 30% two years earlier.
2. Selling on the secondary market
A secondary market platform connects you with verified, accredited buyers when you want liquidity rather than when your company schedules it. This is the only path where you control the timing.
The trade-off is that you're responsible for navigating pricing, documentation, and company approval — which is exactly why the platform you choose matters.
3. Waiting
Sometimes correct, and worth stating honestly. If your company has confidentially filed and a listing looks near, waiting may maximize value. Anthropic filed confidentially in June 2026 with a listing possible as early as October 2026.
But waiting is a decision, not a default. IPO timelines slip constantly, and concentration risk compounds the longer you hold — particularly if the same company also pays your salary.
4. Share-backed financing
Some lenders will advance cash against private shares. You keep the upside but take on debt secured by an illiquid, hard-to-value asset. If the valuation falls, you can owe more than the position is worth. Approach with real caution and professional advice.
The Approval Process Nobody Warns You About
Here's what surprises most first-time sellers: you generally cannot just sell your shares. Private company stock comes with contractual restrictions, and several parties may have a say.
Right of first refusal (ROFR)
Most private companies hold a ROFR: once you agree a price with an outside buyer, the company (or its designees) can step in and buy the shares on those same terms.
This is not theoretical. On platforms built around direct transfers, Hiive's direct transfers saw ROFR exercised at a roughly 18% rate in 2024 — nearly one in five agreed deals redirected away from the original buyer. For you as the seller, a ROFR exercise usually still means you get paid; but it can delay closing and it means your buyer relationship may evaporate.
Transfer restrictions and board approval
Your stock agreement may prohibit transfers outright without board consent. Companies enforce this aggressively — OpenAI has warned that SPVs and transfers made without board approval are void and won't be recognized on its cap table.
For a seller, that's a warning worth internalizing: a transaction structured improperly may not merely be delayed, it may be legally ineffective. Selling through a regulated broker-dealer that handles company approval properly protects you as much as it protects the buyer.
Other common restrictions
Lock-ups around financing events or an anticipated IPO.
Volume caps limiting what percentage of your holdings you can sell.
Blackout periods tied to company milestones.
Information restrictions — you may be contractually barred from sharing company financials with a prospective buyer, which complicates pricing.
What to Do Before You Sell
Read your paperwork. Stock agreement, option grant, and any shareholder agreement. Find the transfer-restriction and ROFR clauses specifically.
Confirm what you actually hold. Vested shares? Unexercised options? Common or preferred? RSUs that haven't settled? These behave very differently.
Understand your tax position before you transact. The tax treatment of a secondary sale can be substantial and depends on your holding period, cost basis, and how you acquired the shares. Talk to a tax professional — and note that QSBS treatment under Section 1202 generally requires acquisition at original issuance, so it typically won't apply to shares you bought on a secondary market.
Get pricing context. Know where your company has been marked across recent secondary activity and its last funding round before you negotiate.
Decide how much to sell. Partial liquidity is a legitimate strategy — taking some risk off the table while keeping exposure to the upside.
Check whether a tender is coming. If your company runs one annually, waiting a few months may be simpler than a bilateral sale.
Selling on AllocationsX
Most platforms are effectively buy-only funnels. AllocationsX is built as a genuine two-sided marketplace, so shareholders seeking liquidity are a first-class use case rather than an afterthought:
Access to verified, accredited buyers — every participant completes accreditation verification.
Regulated execution. AllocationsX is operated by Allocations Securities, LLC, an SEC-registered broker-dealer and member of FINRA and SIPC, operating an Alternative Trading System under Regulation ATS — the structure that matters most when companies are voiding improperly papered transfers.
Reference pricing data so you're not negotiating your own exit blind.
Documentation, transfer process, and funding handled on-platform, end to end.
Liquidity on your timeline, not only when your company opens a tender window.
Explore liquidity for shares you already hold. Launch the AllocationsX app →
FAQ: Selling Pre-IPO Shares
Can I sell my pre-IPO shares whenever I want?
Usually not freely. Most private company stock carries transfer restrictions requiring company or board approval, and most companies hold a right of first refusal. Check your stock agreement, and expect an approval step in any sale.
What is a tender offer and how do I get into one?
A tender offer is a company-run liquidity event with a set price and a window of typically two to four weeks. You can't initiate one — the company does. About 110 issuers ran a board-sponsored tender in the 12 months to mid-2026, roughly triple the 2021 level.
What happens if the company exercises its ROFR?
The company (or its designees) buys your shares on the same terms you negotiated with the outside buyer. You generally still sell at your agreed price, but closing may be delayed and your original buyer doesn't get the shares. Roughly 18% of Hiive's direct transfers saw ROFR exercised in 2024.
Do I owe taxes when I sell pre-IPO shares?
Almost certainly, and the treatment depends on your cost basis, holding period, and how you acquired the shares. QSBS treatment under Section 1202 generally requires acquisition at original issuance, so it typically doesn't apply to secondary purchases. This is genuinely worth a conversation with a tax professional before you transact — nothing here is tax advice.
Should I sell now or wait for the IPO?
That depends on your concentration risk, your liquidity needs, and how near a listing realistically is — and IPO timelines slip often. Many shareholders take partial liquidity as a middle path. It's a personal financial decision; consider discussing it with a licensed advisor.
AllocationsX is operated by Allocations Securities, LLC, an SEC-registered broker-dealer and member of FINRA and SIPC, operating an Alternative Trading System under Regulation ATS. Available to accredited and qualified investors only; verification required. Private investments involve significant risk, including illiquidity and possible loss of principal. Valuations referenced are indicative, based on secondary-market activity or last funding rounds, and may not reflect executable prices. Nothing in this article constitutes tax, legal, investment, or accounting advice.
